17 August 2026
17 August 2026
Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.
The submission is supported by efficacy and safety data from the Phase III VALOR clinical trial.
Lantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.
Spevatamig is a bispecific antibody targeting claudin 18.2 and CD47, designed to function as an innate immunity enhancer.
Khartis was co-founded two years ago by the team at XinThera, a biotech acquired by Gilead.
In combination with ZDd, Zenbexus received the agency’s decision following results from the Phase III EXCALIBER-RRMM trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
